Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520142186> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2520142186 endingPage "e296" @default.
- W2520142186 startingPage "e295" @default.
- W2520142186 abstract "Objective: Insulin resistance (IR) is evident in Chronic Kidney Disease (CKD ) even in non-diabetic patient, although the clinical relevances remain to be determined. We reported that aldosterone increase in CKD is contributed to IR in CKD and MR antagonist, spironolactone ameliorated IR in CKD in three months treatment. We follow our CKD cohort for five years and explored the relevance of IR in the progression of CKD. We also performed procebo-controlled clinical trial using mineralocorticoid receptor antagonist eplerenone and examined its effects on the progression of CKD. Design and Method: Between 2007 and 2008, consecutive 197 patients with CKD were enrolled and followed these patients for five years. Risk factors for the progression of CKD evaluated by the rate of eGFR decline was determined by multiple regression analysis. We recruited the patients with hyperaldosterone and IR patients (N = 48) and treated them with eprelenone (N = 22) and placebo (N = 26) for three years and evaluated its effect on eGFR decline. Results: In CKD patients, HOMA-IR levels were negatively associated with eGFR levels. Plasma aldosterone concentration was determined as an independent risk factor for HOMA-IR levels. After three years follow-up, baseline HOMA-IR levels was significantly associated with eGFR decline and selected as a independent risk factor. We classified quartile groups depending on the baseline HOMA-IR levels and found out the 3rd and 4th quartile groups were significantly higher decline in eGFR. Finally, eplereneone ameliorated eGFR decline of non-diabetic CKD patients with high HOMA-IR and high plasm aldosterone levels(eplerenone; eGFR 51.0 ± 3.7→50.4 ± 3.4 ml/min, placebo; eGFR 55.6 ± 5.1→53.1 ± 4.7 ml/min). Conclusions: IR is a risk factor of the progression of CKD and mineralocorticoid receptor antagonist will provide a novel strategy against the progression of CKD through the amelioration of IR." @default.
- W2520142186 created "2016-09-23" @default.
- W2520142186 creator A5008929134 @default.
- W2520142186 creator A5015476095 @default.
- W2520142186 creator A5026898221 @default.
- W2520142186 creator A5036863557 @default.
- W2520142186 creator A5040271448 @default.
- W2520142186 creator A5077665206 @default.
- W2520142186 creator A5089373241 @default.
- W2520142186 date "2016-09-01" @default.
- W2520142186 modified "2023-10-14" @default.
- W2520142186 title "PS 08-11 THE EFFECT OF MINERALOCORTICOID ANTAGONIST ON RENAL INSULIN RESISTANCE AND THE PROGRESSION OF RENAL FAILURE IN NON-DIABETIC CKD PATIENTS" @default.
- W2520142186 doi "https://doi.org/10.1097/01.hjh.0000500706.33930.1a" @default.
- W2520142186 hasPublicationYear "2016" @default.
- W2520142186 type Work @default.
- W2520142186 sameAs 2520142186 @default.
- W2520142186 citedByCount "0" @default.
- W2520142186 crossrefType "journal-article" @default.
- W2520142186 hasAuthorship W2520142186A5008929134 @default.
- W2520142186 hasAuthorship W2520142186A5015476095 @default.
- W2520142186 hasAuthorship W2520142186A5026898221 @default.
- W2520142186 hasAuthorship W2520142186A5036863557 @default.
- W2520142186 hasAuthorship W2520142186A5040271448 @default.
- W2520142186 hasAuthorship W2520142186A5077665206 @default.
- W2520142186 hasAuthorship W2520142186A5089373241 @default.
- W2520142186 hasConcept C126322002 @default.
- W2520142186 hasConcept C134018914 @default.
- W2520142186 hasConcept C189135053 @default.
- W2520142186 hasConcept C2776379505 @default.
- W2520142186 hasConcept C2777391703 @default.
- W2520142186 hasConcept C2778525890 @default.
- W2520142186 hasConcept C2778653478 @default.
- W2520142186 hasConcept C2779306644 @default.
- W2520142186 hasConcept C2780072264 @default.
- W2520142186 hasConcept C555293320 @default.
- W2520142186 hasConcept C71924100 @default.
- W2520142186 hasConceptScore W2520142186C126322002 @default.
- W2520142186 hasConceptScore W2520142186C134018914 @default.
- W2520142186 hasConceptScore W2520142186C189135053 @default.
- W2520142186 hasConceptScore W2520142186C2776379505 @default.
- W2520142186 hasConceptScore W2520142186C2777391703 @default.
- W2520142186 hasConceptScore W2520142186C2778525890 @default.
- W2520142186 hasConceptScore W2520142186C2778653478 @default.
- W2520142186 hasConceptScore W2520142186C2779306644 @default.
- W2520142186 hasConceptScore W2520142186C2780072264 @default.
- W2520142186 hasConceptScore W2520142186C555293320 @default.
- W2520142186 hasConceptScore W2520142186C71924100 @default.
- W2520142186 hasIssue "Supplement 1" @default.
- W2520142186 hasLocation W25201421861 @default.
- W2520142186 hasOpenAccess W2520142186 @default.
- W2520142186 hasPrimaryLocation W25201421861 @default.
- W2520142186 hasRelatedWork W1971595373 @default.
- W2520142186 hasRelatedWork W2037408526 @default.
- W2520142186 hasRelatedWork W2072829430 @default.
- W2520142186 hasRelatedWork W2168712739 @default.
- W2520142186 hasRelatedWork W2312942238 @default.
- W2520142186 hasRelatedWork W2516746587 @default.
- W2520142186 hasRelatedWork W2589899659 @default.
- W2520142186 hasRelatedWork W2981713925 @default.
- W2520142186 hasRelatedWork W32200126 @default.
- W2520142186 hasRelatedWork W4293597390 @default.
- W2520142186 hasVolume "34" @default.
- W2520142186 isParatext "false" @default.
- W2520142186 isRetracted "false" @default.
- W2520142186 magId "2520142186" @default.
- W2520142186 workType "article" @default.